Allogene Therapeutics (NASDAQ: ALLO) is one of 114 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its competitors? We will compare Allogene Therapeutics to related companies based on the strength of its profitability, institutional ownership, dividends, analyst recommendations, valuation, earnings and risk.
This table compares Allogene Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Allogene Therapeutics Competitors||-5,144.22%||-64.24%||-27.96%|
This table compares Allogene Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Allogene Therapeutics Competitors||$897.64 million||$190.37 million||-1.26|
Allogene Therapeutics’ competitors have higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current ratings and price targets for Allogene Therapeutics and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Allogene Therapeutics Competitors||837||2781||6069||261||2.58|
Allogene Therapeutics currently has a consensus target price of $38.20, indicating a potential upside of 47.21%. As a group, “Biological products, except diagnostic” companies have a potential upside of 39.79%. Given Allogene Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Allogene Therapeutics is more favorable than its competitors.
Insider and Institutional Ownership
51.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 48.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 16.4% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Allogene Therapeutics beats its competitors on 7 of the 11 factors compared.
About Allogene Therapeutics
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma. Its preclinical product candidates include ALLO-715, an allogeneic CAR T cell product candidate for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; CD70 to treat renal cell cancer; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepletion agent. The company was founded in 2017 and is headquartered in South San Francisco, California.
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.